Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is … Continue reading “QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray”
Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The … Continue reading “Silo Pharma Inc. (SILO) Is ‘One to Watch’”
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, … Continue reading “QualityStocksNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments”
Designed to merge ideas with investment, NobleCon18 (the first full in-person NobleCon since February 2020) will feature 100+ carefully selected emerging growth public companies. With total attendance limited to 1,000, this ideal-sized event will provide investors with more direct access to executive teams over the course of the two-day conference. Taking place at The Guitar … Continue reading “Sneak Peek at NobleCon18’s Current Lineup of Keynotes & Moderators”
Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing … Continue reading “Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials”
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board (“IRB”) for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for … Continue reading “QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study”
Investment Considerations Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints. In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous … Continue reading “Silo Pharma Inc. (NASDAQ: SILO)”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be represented at three upcoming events: the Scottsdale Capital Event, Planet MicroCap Showcase and H.C. Wainwright Annual Global Life Sciences Conference. Delic CEO and cofounder Matt Stang will present at each event, including providing an … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Participating, Presenting at Upcoming Investor Conferences”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, aims to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”). The chain operates in multiple locations, strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients. … Continue reading “QualityStocksNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Scalable Approach to Psychedelic-Based Treatments Aimed at ‘Giving People Their Best Selves Back’”
Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials Mydecine’s management has optimism for the future, as it taps … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences”
